| Literature DB >> 25504150 |
Duk Kyung Kim1, Hyun S Lillehoj2, Seung I Jang2, Sung Hyen Lee3, Yeong Ho Hong4, Hans H Cheng5.
Abstract
Necrotic enteritis (NE) is an important intestinal infectious disease of commercial poultry flocks caused by Clostridium perfringens. Using an experimental model of NE involving co-infection with C. perfringens and Eimeria maxima, transcriptome profiling and functional genomics approaches were applied to identify the genetic mechanisms that might regulate the host response to this disease. Microarray hybridization identified 1,049 transcripts whose levels were altered (601 increased, 448 decreased) in intestinal lymphocytes from C. perfringens/E. maxima co-infected Ross chickens compared with uninfected controls. Five biological functions, all related to host immunity and inflammation, and 11 pathways were identified from this dataset. To further elucidate the role of host genetics in NE susceptibility, two inbred chicken lines, ADOL line 6 and line 7 which share an identical B2 major histocompatibility complex haplotype but differ in their susceptibility to virus infection, were compared for clinical symptoms and the expression levels of a panel of immune-related genes during experimental NE. Line 6 chickens were more susceptible to development of experimental NE compared with line 7, as revealed by decreased body weight gain and increased E. maxima oocyst shedding. Of 21 immune-related genes examined, 15 were increased in C. perfringens/E. maxima co-infected line 6 vs. line 7 chickens. These results suggest that immune pathways are activated in response to experimental NE infection and that genetic determinants outside of the chicken B complex influence resistance to this disease.Entities:
Mesh:
Year: 2014 PMID: 25504150 PMCID: PMC4263703 DOI: 10.1371/journal.pone.0114960
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Oligonucleotide primers used for qRT-PCR.
| Gene Symbol | Primer Sequence (5′→3′) | Entrez Gene Name | GenBank Accession No. | |
| LCP1 | Forward |
| Lymphocyte cytosolic protein 1 (L-plastin) | NM_001008440.1 |
| Reverse |
| |||
| MTTP | Forward |
| Microsomal triglyceride transfer protein | NM_001109784.1 |
| Reverse |
| |||
| CALB1 | Forward |
| Calbindin 1, 28 kDa | NM_205513.1 |
| Reverse |
| |||
| CXCL14 | Forward |
| Chemokine (C-X-C motif) ligand 14 | NM_204712.2 |
| Reverse |
| |||
| ANXA1 | Forward |
| Annexin A1 | NM_206906.1 |
| Reverse |
| |||
| IL8 | Forward |
| Interleukin 8 | AJ009800 |
| Reverse |
| |||
| APP | Forward |
| Amyloid beta (A4) precursor protein | NM_204308 |
| Reverse |
| |||
| ARHGEF6 | Forward |
| Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 | NM_001006432 |
| Reverse |
| |||
| BCL2 | Forward |
| B-cell CLL/lymphoma 2 | NM_205339 |
| Reverse |
| |||
| COL1A2 | Forward |
| Collagen, type I, alpha 2 | NM_001079714 |
| Reverse |
| |||
| CXCL14 | Forward |
| Cchemokine (C-X-C motif) ligand 14 | NM_204712 |
| Reverse |
| |||
| GJA1 | Forward |
| Gap junction protein, alpha 1, 43 kDa | NM_204586 |
| Reverse |
| |||
| HSP90B1 | Forward |
| Heat shock protein 90 kDa beta (Grp94), member 1 | NM_204289 |
| Reverse |
| |||
| NFKBIZ | Forward |
| Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta | NM_001006254 |
| Reverse |
| |||
| SERPINF1 | Forward |
| Serpin peptidase inhibitor, clade F, member 1 | NM_001257289 |
| Reverse |
| |||
| SOCS3 | Forward |
| Suppressor of cytokine signaling 3 | NM_204600 |
| Reverse |
| |||
| SOCS6 | Forward |
| Suppressor of cytokine signaling 6 | NM_001127312 |
| Reverse |
| |||
| TAB3 | Forward |
| TGF-beta activated kinase 1/MAP3K7 binding protein 3 | XM_416787 |
| Reverse |
| |||
| TCF12 | Forward |
| Transcription factor 12 | NM_205375 |
| Reverse |
| |||
| TNFRSF11B | Forward |
| Tumor necrosis factor receptor superfamily, member 11 b | NM_001033641 |
| Reverse |
| |||
| TRAF3 | Forward |
| TNF receptor-associated factor 3 | XM_421378 |
| Reverse |
| |||
| VEGFA | Forward |
| Vascular endothelial growth factor A | NM_001110355 |
| Reverse |
| |||
| LITAF | Forward |
| Lipopolysaccharide-induced TNF factor | AY765397 |
| Reverse |
| |||
| GAPDH | Forward |
| Glyceraldehyde-3-phosphate dehydrogenase | NM_204305 |
| Reverse |
|
Figure 1Effect of C. perfringens/E. maxima co-infection of Ross chickens on body weight gains and intestinal lesion scores.
(A) Chickens were uninfected (Control) or co-infected with C. perfringens and E. maxima (NE) and body weight gains were measured between days 0–9 post-infection with E. maxima. (B) Gut lesion scores were determined at day 2 post-infection with C. perfringens on a scale from 0 (none) to 4 (high) in a blinded fashion by three independent observers. Each bar represents the mean ± SD value (n = 8). *, P<0.05; ***, P<0.001.
The 20 most up-regulated and 20 most down-regulated intestinal IEL transcript levels in C. perfringens/E. maxima co-infected Ross chickens compared with uninfected controls.
| Symbol | Entrez Gene Name | Fold Change | Location | Type(s) |
|
| ||||
| MMP7 | Matrix metallopeptidase-7 | 45.476 | Extracellular Space | Peptidase |
| LYG2 | Lysozyme G-like 2 | 35.509 | Extracellular Space | Enzyme |
| VCAM1 | Vascular cell adhesion molecule 1 | 14.508 | Plasma Membrane | Other |
| ATP13A4 | ATPase type 13A4 | 12.263 | Unknown | Transporter |
| BATF3 | Basic leucine zipper transcription factor, ATF-like 3 | 11.368 | Nucleus | Transcription Regulator |
| TAC1 | Tachykinin, precursor 1 | 9.837 | Extracellular Space | Other |
| C3 | Complement component 3 | 9.8 | Extracellular Space | Peptidase |
| SOCS1 | Suppressor of cytokine signaling 1 | 9.571 | Cytoplasm | Other |
| LAG3 | Lymphocyte-activation gene 3 | 9.217 | Plasma Membrane | Transmembrane Receptor |
| GLDC | Glycine dehydrogenase (decarboxylating) | 8.991 | Cytoplasm | Enzyme |
| IL21R | Interleukin 21 receptor | 8.101 | Plasma Membrane | Transmembrane Receptor |
| RRM2 | Ribonucleotide reductase M2 | 7.797 | Nucleus | Enzyme |
| SAMHD1 | SAM domain and HD domain 1 | 7.729 | Nucleus | Enzyme |
| MIS12 | MIS12, MIND kinetochore complex component, homolog (S. pombe) | 7.474 | Nucleus | Other |
| CSF2RA | Colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) | 7.444 | Plasma Membrane | Transmembrane Receptor |
| IRG1 | Immunoresponsive 1 homolog (mouse) | 7.171 | Unknown | Other |
| MDFI | MyoD family inhibitor | 7.161 | Cytoplasm | Other |
| TRAIP | TRAF interacting protein | 7.09 | Cytoplasm | Other |
| SFTPA1 | Surfactant protein A1 | 7.003 | Extracellular Space | Transporter |
| SMC2 | Structural maintenance of chromosomes 2 | 6.872 | Nucleus | Transporter |
|
| ||||
| C13orf15 | Chromosome 13 open reading frame 15 | −104.868 | Cytoplasm | Other |
| AGXT2L1 | Alanine-glyoxylate aminotransferase 2-like 1 | −70.677 | Unknown | Enzyme |
| CMBL | Carboxymethylenebutenolidase homolog (Pseudomonas) | −28.026 | Unknown | Enzyme |
| HES6 | Hairy and enhancer of split 6 (Drosophila) | −25.238 | Nucleus | Transcription Regulator |
| RBPMS2 | RNA binding protein with multiple splicing 2 | −22.282 | Unknown | Other |
| S100B | S100 calcium binding protein B | −17.322 | Cytoplasm | Other |
| SERPINF1 | Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1 | −17.216 | Extracellular Space | Other |
| SERPINB2 | Serpin peptidase inhibitor, clade B (ovalbumin), member 2 | −16.241 | Extracellular Space | Other |
| BBOX1 | Butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1 | −15.873 | Cytoplasm | Enzyme |
| RHAG | Rh-associated glycoprotein | −13.518 | Plasma Membrane | Peptidase |
| CXCL14 | Chemokine (C-X-C motif) ligand 14 | −13.029 | Extracellular Space | Cytokine |
| MYL10 | Myosin, light chain 10, regulatory | −12.77 | Cytoplasm | Other |
| TMEM199 | Transmembrane protein 199 | −12.112 | Unknown | Other |
| ANXA1 | Annexin A1 | −11.609 | Plasma Membrane | Other |
| NRG4 | Neuregulin 4 | −11.399 | Extracellular Space | Growth Factor |
| ALDH1A1 | Aldehyde dehydrogenase 1 family, member A1 | −10.85 | Cytoplasm | Enzyme |
| RNF152 | Ring finger protein 152 | −10.558 | Cytoplasm | Enzyme |
| COL1A2 | Collagen, type I, alpha 2 | −10.196 | Extracellular Space | Other |
| SYNM | Synemin, intermediate filament protein | −9.059 | Cytoplasm | Other |
| CALB1 | Calbindin 1, 28 kDa | −8.966 | Cytoplasm | Other |
The biological functions significantly associated with the differentially expressed transcripts in C. perfringens/E. maxima co-infected Ross chickens compared with uninfected controls.
| Functions Annotation | Category |
| No. of Genes |
| Immune response | Inflammatory Response | 5.93E-12 | 83 |
| Cell movement of leukocytes | Cellular Movement | 1.36E-09 | 49 |
| Hematological System Development and Function | |||
| Immune Cell Trafficking | |||
| Quantity of leukocytes | Hematological System Development and Function | 1.96E-09 | 45 |
| Tissue Morphology | |||
| Cell movement of blood cells | Cellular Movement | 2.21E-09 | 53 |
| Quantity of mononuclear leukocytes | Hematological System Development and Function | 2.52E-09 | 38 |
| Tissue Morphology |
The IPA pathways significantly associated with the differentially expressed transcripts in C. perfringens/E. maxima co-infected Ross chickens compared with uninfected controls.
| Ingenuity Canonical Pathway |
| Ratio |
| Leukocyte Extravasation Signaling | 1.58E-03 | 7.00E-02 |
| Relaxin Signaling | 1.82E-03 | 6.96E-02 |
| LPS/IL-1 Mediated Inhibition of RXR Function | 2.29E-03 | 5.83E-02 |
| Pyruvate Metabolism | 2.82E-03 | 5.19E-02 |
| Neuroprotective Role of THOP1 in Alzheimer's Disease | 2.88E-03 | 9.26E-02 |
| HIF1α Signaling | 2.95E-03 | 8.33E-02 |
| ATM Signaling | 7.08E-03 | 1.11E-01 |
| HMGB1 Signaling | 7.41E-03 | 8.00E-02 |
| Tight Junction Signaling | 8.32E-03 | 6.10E-02 |
| ILK Signaling | 9.33E-03 | 6.22E-02 |
| Hepatic Fibrosis/Hepatic Stellate Cell Activation | 9.77E-03 | 6.80E-02 |
*The ratio of the number of genes from the dataset mapped to the indicated pathway divided by the total number of genes within that particular pathway.
Genes included in the three canonical pathways most significantly associated with the differentially expressed transcripts in C. perfringens/E. maxima co-infected Ross chickens compared with uninfected controls.
| Pathway | Gene Symbol | Entrez Gene Name | Fold Change | Location | Type(s) |
| Leukocyte Extravasation Signaling | CD99 | CD99 molecule | −4.524 | Plasma Membrane | Other |
| ACTC1 | Actin, alpha, cardiac muscle 1 | −3.201 | Cytoplasm | Enzyme | |
| CTTN | Cortactin | −2.679 | Plasma Membrane | Other | |
| MAPK9 | Mitogen-activated protein kinase 9 | −2.154 | Cytoplasm | Kinase | |
| ARHGAP12 | Rho GTPase activating protein 12 | −2.1 | Cytoplasm | Other | |
| CLDN3 | Claudin 3 | −2.098 | Plasma Membrane | Transmembrane Receptor | |
| FER | Fer (fps/fes related) tyrosine kinase | 2.279 | Cytoplasm | Kinase | |
| PIK3R5 | Phosphoinositide-3-kinase, regulatory subunit 5 | 2.584 | Cytoplasm | Kinase | |
| MMP9 | Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) | 3.071 | Extracellular Space | Peptidase | |
| NCF2 | Neutrophil cytosolic factor 2 | 3.464 | Cytoplasm | Enzyme | |
| PIK3CD | Phosphoinositide-3-kinase, catalytic, delta polypeptide | 3.775 | Cytoplasm | Kinase | |
| RAC2 | Ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2) | 3.919 | Cytoplasm | Enzyme | |
| VCAM1 | Vascular cell adhesion molecule 1 | 14.508 | Plasma Membrane | Other | |
| MMP7 | Matrix metallopeptidase 7 (matrilysin, uterine) | 45.476 | Extracellular Space | Peptidase | |
| Relaxin Signaling | MPPE1 | Metallophosphoesterase 1 | 2.005 | Cytoplasm | Enzyme |
| PDE3B | Phosphodiesterase 3B, cGMP-inhibited | 2.18 | Cytoplasm | Enzyme | |
| PIK3CD | Phosphoinositide-3-kinase, catalytic, delta polypeptide | 3.775 | Cytoplasm | Kinase | |
| PIK3R5 | Phosphoinositide-3-kinase, regulatory subunit 5 | 2.584 | Cytoplasm | Kinase | |
| MMP9 | Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) | 3.071 | Extracellular Space | Peptidase | |
| VEGFA | Vascular endothelial growth factor A | −2.245 | Extracellular Space | Growth Factor | |
| CREB1 | cAMP responsive element binding protein 1 | 2.05 | Nucleus | Transcription Regulator | |
| ADCY5 | Adenylate cyclase 5 | −2.53 | Plasma Membrane | Enzyme | |
| ADCY9 | Adenylate cyclase 9 | −3.136 | Plasma Membrane | Enzyme | |
| GNA11 | Guanine nucleotide binding protein (G protein), alpha 11 (Gq class) | −2.271 | Plasma Membrane | Enzyme | |
| GNG13 | Guanine nucleotide binding protein (G protein), gamma 13 | −3.434 | Plasma Membrane | Enzyme | |
| LPS/IL-1 Mediated Inhibition of RXR Function | ACSBG2 | Acyl-CoA synthetase bubblegum family member 2 | 2.046 | Cytoplasm | Enzyme |
| ACSL5 | Acyl-CoA synthetase long-chain family member 5 | 4.067 | Cytoplasm | Enzyme | |
| ALDH1A1 | Aldehyde dehydrogenase 1 family, member A1 | −10.85 | Cytoplasm | Enzyme | |
| CYP3A4 | Cytochrome P450, family 3, subfamily A, polypeptide 4 | 2.265 | Cytoplasm | Enzyme | |
| FABP5 | Fatty acid binding protein 5 (psoriasis-associated) | −2.642 | Cytoplasm | Transporter | |
| GSTT1 | Glutathione S-transferase theta 1 | −2.622 | Cytoplasm | Enzyme | |
| HMGCS2 | 3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) | −6.489 | Cytoplasm | Enzyme | |
| MAPK9 | Mitogen-activated protein kinase 9 | −2.154 | Cytoplasm | Kinase | |
| SMOX | Spermine oxidase | −2.372 | Cytoplasm | Enzyme | |
| HS6ST1 | Heparan sulfate 6-O-sulfotransferase 1 | 2.632 | Plasma Membrane | Enzyme | |
| SLC27A4 | Solute carrier family 27 (fatty acid transporter), member 4 | 2.839 | Plasma Membrane | Transporter | |
| TNFRSF11B | Tumor necrosis factor receptor superfamily, member 11b | −4.19 | Plasma Membrane | Transmembrane Receptor | |
| TNFRSF1B | Tumor necrosis factor receptor superfamily, member 1B | 4.62 | Plasma Membrane | Transmembrane Receptor |
Figure 2The first (A) and seventh (B) networks of genes most significantly associated with the differentially expressed transcripts in C. perfringens/E. maxima co-infected Ross chickens compared with uninfected controls.
Up- and down-regulated genes are illustrated by red and green, respectively. The color intensity directly correlates with the difference in the expression level of the corresponding gene compared between line 6 and line 7 chickens.
Figure 3Comparison of the fold changes in the expression levels of 15 immune-related gene transcripts in intestinal IELs of C. perfringens/E. maxima co-infected Ross chickens (NE) compared with uninfected controls (Control).
Transcript levels were analyzed by microarray hybridization and qRT-PCR in both groups. Each bar represents the mean ± SD value of the fold change in the transcript level (n = 3). ANXA1, Annexin A1; APP, Amyloid precursor protein; ARHGEF6, Rho guanine nucleotide exchange factor 6; CALB1, Calbindin 1; COL1A2, Collagen, type 1, alpha 2; CXCL14, Chemokine (C-X-C motif) ligand 14; GJA1, Gap junction alpha 1; HSP90B1, Heat shock protein 90kDa beta 1; VEGFA, Vascular endothelial growth factor A; ALCAM, Activated leukocyte cell adhesion molecule; MTTP, Microsomal triglyceride transfer protein; LCP1, Lymphocyte cytosolic protein 1; TNFSF11B, Tumor necrosis factor superfamily 11; SERPINE1, Serpin peptidase inhibitor, clade F1.
Figure 4Effect of C. perfringens/E. maxima co-infection of ADOL line 6 and line 7 chickens on body weight gains and oocyst shedding.
(A) Chickens were uninfected (Control) or co-infected with C. perfringens and E. maxima (NE) and body weight gains were measured between days 0–9 post-infection with E. maxima. Bars with different letters are significantly different according to the Duncan's multiple range test (P<0.05). (B) Fecal oocyst shedding was measured between days 0–9 post-infection with E. maxima in C. perfringens/E. maxima co-infected chickens. Each bar represents the mean ± SD value (n = 8). *, P<0.05.
Immune-related intestinal IEL transcript levels in uninfected and in C. perfringens/E. maxima co-infected ADOL line 6 and line 7 chickens.
| Gene | Treatment | ADOL Line 6 | ADOL Line 7 |
| ANXA1 | Uninfected | 3.6E-03±2.5E-04c | 6.5E-03±4.5E-04b |
| NE | 1.0E-02±7.4E-05a | 1.6E-03±9.4E-05bc | |
| ARHGEF6 | Uninfected | 1.9E-03±7.8E-06c | 2.4E-03±6.9E-05b |
| NE | 3.3E-03±1.0E-04a | 2.6E-03±9.9E-05b | |
| LITAF | Uninfected | 2.0E+00±3.6E-01b | 6.7E-01±2.6E-02c |
| NE | 4.8E+00±2.7E-01a | 8.3E-01±3.7E-02c | |
| SOCS3 | Uninfected | 1.3E-08±1.9E-09b | 4.0E-07±1.6E-08b |
| NE | 3.0E-06±1.1E-07a | 9.2E-07±3.5E-08b | |
| BCL2 | Uninfected | 2.7E-04±1.6E-05b | 5.1E-04±2.1E-05a |
| NE | 2.2E-04±7.4E-06b | 1.3E-04±9.3E-06c | |
| GJA1 | Uninfected | 5.5E-05±3.5E-06a | 1.8E-05±3.4E-06b |
| NE | 1.2E-05±3.7E-07b | 1.6E-05±9.7E-07b | |
| IL8 | Uninfected | 1.5E+00±1.0E-01a | 7.2E-01±6.3E-02b |
| NE | 5.7E-01±1.1E-02b | 4.4E-01±6.2E-02b | |
| SOCS6 | Uninfected | 7.5E-04±3.9E-05a | 2.6E-04±6.7E-06b |
| NE | 2.6E-04±9.7E-06b | 2.3E-04±8.1E-06b | |
| HSP90B1 | Uninfected | 1.2E-02±2.1E-04b | 1.3E-02±3.0E-04b |
| NE | 1.6E-02±3.8E-04a | 3.9E-03±8.1E-05c | |
| VEGFA | Uninfected | 2.6E-02±3.6E-04b | 2.8E-02±6.0E-04b |
| NE | 4.1E-02±4.0E-04a | 1.6E-02±3.1E-04c | |
| MTTP | Uninfected | 6.1E-06±1.7E-07bc | 3.1E-06±9.4E-08c |
| NE | 2.9E-05±6.2E-07a | 9.4E-06±7.2E-07b | |
| SERPINF1 | Uninfected | 3.8E-04±2.2E-05b | 1.5E-03±2.7E-05a |
| NE | 7.7E-05±2.1E-06c | 1.3E-04±8.0E-06c | |
| CALB1 | Uninfected | 2.6E+00±7.5E-02a | 7.3E-01±3.5E-02b |
| NE | 3.7E-03±6.0E-05c | 5.7E-02±9.2E-03c | |
| LCP1 | Uninfected | 3.4E-06±2.8E-07c | 2.8E-06±3.5E-07c |
| NE | 3.2E-05±3.8E-07a | 4.6E-05±3.9E-06b | |
| TNFRSF11B | Uninfected | 1.9E-07±9.5E-09a | 1.3E-07±2.3E-08b |
| NE | 1.0E-07±9.2E-09b | 3.3E-08±5.4E-09c | |
| COL1A2 | Uninfected | 2.9E-04±2.8E-05ab | 3.7E-04±2.6E-05a |
| NE | 1.2E-04±7.3E-06c | 2.4E-04±2.7E-05b | |
| TCF12 | Uninfected | 2.3E-04±1.4E-05a | 1.1E-04±1.2E-05b |
| NE | 1.6E-04±2.7E-05b | 6.1E-05±3.5E-06c | |
| APP | Uninfected | 1.9E-02±1.2E-04a | 1.2E-02±3.0E-04b |
| NE | 1.1E-02±3.0E-04b | 5.1E-03±1.4E-04c | |
| CXCL14 | Uninfected | 9.6E-04±5.4E-05a | 2.6E-04±1.5E-05b |
| NE | 3.1E-04±7.7E-05b | 5.2E-05±4.8E-06c | |
| NFKBIZ | Uninfected | 2.4E-03±9.9E-05b | 6.0E-03±1.6E-04a |
| NE | 1.8E-03±4.6E-05c | 1.3E-03±1.5E-05d | |
| TAB3 | Uninfected | 1.9E-03±1.2E-05a | 1.2E-03±1.2E-05b |
| NE | 4.4E-04±1.6E-05c | 2.4E-04±1.1E-05d | |
| TRAF3 | Uninfected | 1.9E-03±3.4E-05a | 6.8E-04±5.1E-06b |
| NE | 6.0E-04±1.9E-05b | 2.5E-04±9.7E-06c |
Each value represents the mean ± SD (n = 3). Within each gene group, values with different superscripts are significantly different according to the Duncan's multiple range test (P<0.05).